A record USD 115 billion private equity surge, explosive AI adoption, and the GLP-1 obesity drug boom are redefining global healthcare investing. Sovereign wealth funds and global investors are scrambling to capture high-growth opportunities across digital health, medtech, metabolic disease therapies, and India–GCC collaborations, as the sector races toward a USD 22 trillion future.